Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59,746,870
-
Total 13F shares
-
33,557,749
-
Share change
-
+33,557,749
-
Total reported value
-
$734,910,999
-
Put/Call ratio
-
0.14%
-
Price per share
-
$21.90
-
Number of holders
-
44
-
Value change
-
+$734,910,939
-
Number of buys
-
44
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q1 2023
As of 31 Mar 2023,
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,557,749 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, 5AM Venture Management, LLC, FMR LLC, CITADEL ADVISORS LLC, VR Adviser, LLC, RA CAPITAL MANAGEMENT, L.P., Cormorant Asset Management, LP, Fairmount Funds Management LLC, COMMODORE CAPITAL LP, and Frazier Life Sciences Management, L.P..
This page lists
44
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.